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Elicitation of type I interferon (IFN-I) has been shown to both enhance and impair cell-me-
diated immune responses in acute and persistent viral infections, respectively. Here, we 
show that, in addition to its effect on T cells, IFN-I drives impairment of specific antibody 
responses through interaction with B cells in the acute phase of lymphocytic chorio-
meningitis virus (LCMV) infection. This impairment was limited to the T cell-dependent 
B cell response and was associated with disruption of B cell follicles, development of 
hypergammaglobulinemia (HGG), and expansion of the T follicular helper cell population. 
Antigen-specific antibody responses were restored by ablation of IFN-I signaling through 
antibody-mediated IFN-I receptor blockade and B cell-specific IFN-I receptor knockout. 
Importantly, IFN-I receptor deficiency in B cells also accelerated the development of 
LCMV neutralizing antibodies and alleviated HGG. These results provide a potential 
therapeutic target toward efficient treatment measures that limit immunopathology in 
persistent viral infections.
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inTrODUcTiOn
The humoral immune response plays a central effector role against viral infection whereby induction 
of effective antibody (Ab) responses serves as an important correlate toward pathogen clearance. 
However, during persistent viral infections, e.g., with human immunodeficiency virus (HIV), hepa-
titis C virus (HCV), or the murine infection model lymphocytic choriomeningitis virus (LCMV), 
emergence of neutralizing Abs (nAbs) against these highly mutable viruses is delayed, initially nar-
row in specificity and ineffective against the established infection; as such, the Ab response bears 
negligible impact on the progression of the disease (1). Accompanying the delayed induction of 
nAbs, infected hosts also exhibit an altered immunological milieu that features aberrancies to the 
humoral response such as: (i) dysregulation of B cell subpopulations (2, 3); (ii) hypergammaglobu-
linemia (HGG) (4, 5); (iii) increase of polyreactive Abs (6, 7); and (iv) impaired response to vaccines 
(4, 8). Altogether, these perturbations result in a diminished antigen-specific Ab response and an 
enhanced non-specific polyclonal response. Notably, these immunomodulatory effects are driven 
directly by viral pathogenic mechanisms and indirectly through immunopathogenesis triggered 
by host antiviral responses (9). Presently, it is yet to be determined whether this immunological 
disruption occurs as a function of chronicity or due to mechanisms initiated during the acute stage 
of the viral infection.
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Concomitant with dysregulation of the humoral immune 
response, an increase in T follicular helper (TFH) cells has also been 
observed during persistent HIV (10) and HCV (11) infections as 
well as the chronic phase of LCMV infection (12). In the LCMV 
model, expansion of TFH cells has been attributed to polarization 
of the CD4 T cell compartment toward TFH responses, which 
suggests a role of cytokines such as type I interferon (IFN-I) 
that skew differentiation and maturation toward TFH and away 
from T helper type 1 (TH1) cells (13). The role of IFN-I signal-
ing with respect to T cells is well characterized and increasing 
evidence shows that this antiviral cytokine has both enhancing 
and immunosuppressive effects on the T cell response upon viral 
infection (14, 15). Two recent studies clearly outlined the bipolar 
effect that IFN-I renders on T cell-mediated immune responses 
by comparing the expression profile of IFN-I and IFN-stimulated 
genes (ISGs) in LCMV Armstrong (acute) versus LCMV Clone 
13 (Cl13; persistent) infection (16, 17). Collectively, this research 
revealed that although protective upon transient elicitation 
such as in acute infections, prolonged elevation of IFN-I levels 
postinfection led to immunosuppression of T cell responses. In 
these studies, sustained expression of IFN-I was shown to drive 
upregulation of immunosuppressive molecules such as PD-1 and 
IL10 as well as disruption of splenic architecture and dampened 
effector CD8+ T cell (CTL) responses (16–21). Altogether, this 
contributes to the failure of viral clearance and eventual persistent 
infection.
Similarly, IFN-I production has also been shown to enhance 
the development of the Ab response against acute viral infections 
or vaccine antigens (22–27). Akin to T cells, the effect of IFN-I 
on B cell responses has been shown to drive increased cellular 
activation and class switching recombination (CSR) in the T-cell-
dependent arm of the humoral immune response (23, 25, 27–29). 
The upregulation of ISGs in B cells from HIV-viremic patients 
(30) is also indicative of a role played by IFN-I during chronic 
infections.
However, unlike the deleterious role played by the cytokine 
against T-cell responses during persistent infection, the effect 
of IFN-I on B cell responses in this context is yet to be fully 
elucidated. In this report, we use the LCMV mouse model to 
further characterize the molecular mechanisms that drive the 
modulation and resulting humoral immune dysregulation during 
persistent virus infection.
resUlTs
lcMV infection impairs the humoral 
response to T-Dependent antigens
Although the influence of escape mutations within the glycopro-
tein envelope of LCMV as well as dysregulated T cell responses 
have been implicated in the late appearance of nAbs (31–33), it 
is unclear whether broader modulation of the immune response 
also contributes to the disrupted Ab response. To directly 
evaluate this, we analyzed the Ab response against the model 
T-dependent (TD) antigen, nitrophenyl (NP) coupled to chicken 
gamma globulin (CGG) in the context of CTL-controlled LCMV 
(34, 35), and Ab-controlled vesicular stomatitis virus  (VSV) 
infection (36). The focal point of these experiments was 
based on the NP response rather than comparing the antiviral 
response to clearly distinguish and determine modulation to 
the global immune response independent of LCMV versus VSV 
whose pathogenic determinants drive distinctive responses. 
C57BL/6 (B6) mice were infected with either LCMV Cl13 or 
LCMV WE (acute); VSV Indiana or mock infected with culture 
media only. All groups were contemporaneously immunized 
with NP-CGG, which predominantly elicits an IgG1 response 
(37). At various time points after immunization, the NP-specific 
IgG1 serum response was monitored by ELISA, which revealed 
that Ab titers were drastically reduced in LCMV Cl13-infected 
mice, compared to VSV-infected or mock-infected control 
mice (Figure 1A). Furthermore, this impairment was also pre-
sent albeit to a lesser extent in mice infected with LCMV WE 
(Figures  1A,B, left panel). Although LCMV-Cl13-associated 
impairment of NP-specific responses declined after day (d)12, 
the increase in the IgG1 responses thereafter did not attain 
the levels observed in VSV-infected or mock-infected groups 
for the duration of the experiment (30 days) (Figure 1A). The 
kinetics of the disrupted NP-specific response and the impact by 
both the acute and persistent strains of LCMV suggest that the 
immunological process that drives this phenotype occurs early 
after infection whereas the Cl13 strain featured more adverse 
impairment due to viral persistence. Upon infection with LCMV 
Cl13 or VSV as above and simultaneous immunization with a 
T-independent Type 2 (TI-2) antigen, NP-FICOLL, NP-specific 
IgG3 (Figure 1C), and IgM (Figure 1D) responses were similar 
in all groups although a trend toward weaker IgM responses in 
the LCMV-infected group was observed at latter time points. 
These results demonstrate that LCMV predominantly impairs 
the TD response. Similar results were also observed in LCMV 
WE-infected mice (data not shown). Despite the impairment of 
the TD response, however, the affinity maturation process was 
unaltered by LCMV Cl13 infection. As illustrated in Figure 1E, 
the ratio of high affinity anti-NP IgG1 Abs binding to NP4-
BSA versus the total anti-NP IgG1 response, measured using 
NP26-BSA, reflected a similar increase in Ab affinity at various 
time points in all three experimental groups. Again, similar 
results were observed for LCMV WE (data not shown). Thus, 
although diminished in serum concentration, the quality of 
the NP-specific response was not affected by LCMV infection. 
Importantly, the reduction in the NP-specific IgG1 response 
occurs in the context of increased total IgG serum levels that is 
evident by d12 in LCMV Cl13- and d8 in LCMV WE-infected 
mice compared to VSV- or mock-infected animals (Figure 1F). 
These results are in agreement with the emergence of poly-
clonal non-specific B cell activation and resultant HGG that is 
observed during LCMV infection (38) and other persistent viral 
infections such as HIV (4, 6) or HCV (39).
To further characterize the duration of LCMV-associated 
effects on the NP-specific response, we immunized mice 4 days 
before (d-4) and on d4, d8, d12, d20, or d30 after LCMV WE or 
VSV infections (Figure S1 in Supplementary Material). In this 
particular experiment, the kinetics of viral clearance within a 
limited window are important to facilitate accurate assessment 
of the effect of Ab-response impairment by LCMV. As such, 
FigUre 1 | lcMV infection impairs the nP-specific ab response in a T cell-dependent manner. B6 mice (four per group) were infected with LCMV Cl13 
(black), LCMV WE (hatched), VSV (gray), or mock infected (white). Mice were immunized the same day (except when indicated otherwise) with an i.p. injection of 
NP53-CGG in alum (a,B,e,F) or NP40-FICOLL in PBS (c,D). (a) NP-specific IgG1 response monitored by ELISA following NP53-CGG immunization. (B) Mice were 
infected as above and immunized with NP53-CGG the same day (d0) or 30 days after infection (d30), and IgG1 NP-specific responses were monitored by ELISA on d8 
postimmunization. NP-specific IgG3 (c) or IgM (D) responses monitored by ELISA following NP40-FICOLL immunization. (e) ELISA plates were coated with NP4-BSA 
or NP26-BSA and high affinity Ab responses were measured as a ratio of Abs binding to NP4-BSA versus the total anti-NP IgG1 response binding to NP26-BSA. 
(F) Total serum IgG responses following concomitant infection and NP53-CGG immunization. Statistical analysis was performed by individual T-tests between 
experimental groups and the mock-infected group. *p < 0.05, **p < 0.01, ***p < 0.001. The dotted line represents detection threshold. (a–e) Representative of two 
independent experiments. (F) Representative of four independent experiments.
3
Daugan et al. LCMV Impairs Antibody Responses through IFN-I
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 564
the acute strain, LCMV WE, was used given that this variant 
is cleared from lymphoid organs within about a week (35). As 
shown in Figure S1A in Supplementary Material, the Ab response 
in the VSV-infected group was unaffected irrespective of the time 
interval between infection and immunization. On the other 
hand, NP-specific IgG1 responses in LCMV WE-infected mice 
revealed similar levels of impairment upon immunization on 
d4, d8, and d12 postimmunization. However, the impact on the 
NP-specific response upon immunization on d4 before or d20 
after infection was less severe relative to the other time points. 
This indicates that B cell responses: (i) were less susceptible to 
LCMV impairment if established prior to infection; (ii) start to 
recover by d20 following LCMV WE infection before returning 
to normal levels by d30 postinfection; and (iii) remain impaired 
past d30 following infection with LCMV Cl13 (Figure  1B, 
right panel). Finally, changes in affinity maturation did not 
attain statistical significance irrespective of the time interval 
between LCMV infection and immunization (Figure S1B in 
Supplementary Material). Taken together, these results indicate 
that LCMV impairs the development of specific Ab responses 
early following establishment of infection, which is sustained in 
the context of persistent infection.
lcMV infection Modifies the lymphoid 
Microenvironment and B cell Function
To gain further insight into the immunological milieu within 
which the impairment of TD NP-specific Ab responses occurred, 
we evaluated B cell populations and the splenic microenvi-
ronment in the three infection groups on d8 postinfection/
immunization. Similar to a previous report (40), we observed 
perturbations in the splenic architecture whereby immunohis-
tochemistry revealed a dramatic disruption of B cell follicles 
in LCMV-infected mice relative to VSV- and mock-infected 
controls with B cells being mostly found outside of the follicles 
(Figure  2A). Counterintuitive to this disruption, while total 
numbers and proportions of splenic B cells were contracted 
in the LCMV Cl13-infected group (Figure  2B), the number 
and proportion of GC B cells were significantly increased 
(Figure 2C). Expansion of the GC B cell population suggested 
enhanced activation of B cells in the LCMV group. Given that 
this phenomenon could lead to increased differentiation into 
effector B cell subsets [e.g., plasma cells (PCs)], we evaluated the 
splenic Ab-secreting cell (ASC) population on d8 after infection 
and immunization with NP-CGG using ELISPOT (Figure 2D). 
In agreement with the expansion of GC B cells and the presence 
FigUre 2 | lcMV infection disrupts the splenic follicular architecture while increasing gc B cell numbers and non-specific ab responses.
(Continued)
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of HGG, the total number of IgG-secreting cells in the LCMV 
Cl13-infected group was elevated. Conversely, the quantity of 
NP-specific IgG-secreting cells was significantly decreased in 
the LCMV Cl13 group, correlating with the depressed antigen-
specific Ab response. Similar results were also observed in the 
bone marrow compartment to which the PCs migrate after 
FigUre 2 | continued  
B6 mice (four per group) were infected with LCMV Cl13 (black), LCMV WE (hatched), VSV (gray), or mock infected (white). Mice were immunized the same day with 
an i.p. injection of NP53-CGG in alum and TD B cell responses were analyzed on d8 after infection. (a) Immunofluorescence showing CD19 (red), MOMA-1 (green), 
and DAPI (blue) expression on spleen sections. (B) Total B cell numbers and proportions were enumerated by flow cytometry. (c) Number and proportion of splenic 
GC B cells. (D) Number of total and NP-specific IgG-secreting cells detected by ELISPOT. (e) Relative Ab secretion of ASCs calculated by ex vivo measurement of 
secreted Abs produced by 105 splenocytes. Statistical analysis was performed by individual T-tests between experimental groups and the mock-infected group. 
*p < 0.05, **p < 0.01, ***p < 0.001. (a) Representative of two independent experiments. (B–e) Representative of four independent experiments.
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differentiation in the secondary lymphoid organs (data not 
shown) and these features were observed in LCMV WE-infected 
animals as well (Figure 2D). Last, consistent with the increase in 
the number of IgG-secreting ASCs due to polyclonal B cell acti-
vation during LCMV infection (38), ASCs from this group also 
displayed an increased secretory capacity (Figure 2E). Expressed 
here as a ratio, the ex vivo Ab concentration from splenic ASCs 
was quantified from culture supernatants, which revealed that 
following LCMV Cl13 infection, ASCs secreted a significantly 
higher quantity of Ab relative to VSV- or mock-infected mice.
lcMV infection Triggers the expansion 
of TFh and an increase in Their 
effector Function
Upon phenotypic characterization of the CD4 T cell compart-
ment, we observed that there was a contraction in the absolute 
number of CD4 T cells (Figure  3A, top panel), which was 
more evident in the proportion of CD4 T cells relative to total 
lymphocytes in the LCMV-infected groups (Figure 3A, bottom 
panel). This coincided with a significant increase in the TFH 
compartment (CD4+CD62L−CD44+CXCR5+Bcl-6+) as shown in 
Figure 3B. These results are supported by previous work, which 
demonstrated that LCMV increased differentiation of CD4 
T cells into TFH, and this redirected differentiation program was 
sustained in LCMV Cl13 due to viral persistence (12). Based on 
these changes in the TFH population and their potential influ-
ence on the humoral immune response, we sought to determine 
whether the essential costimulatory and signaling molecules that 
comprise interaction between TFH and GC B cells were similarly 
modified during LCMV infection. Using phenotypic analysis 
by flow cytometry, we analyzed the expression of PD-1, which 
has been shown to be an ideal marker to distinguish GC from 
non-GC TFH (41). Here, we observed a significantly higher pro-
portion of TFH cells expressing increased levels of PD-1 in LCMV 
Cl13-infected mice (Figure 3C) indicating a higher number of 
GC TFH relative to the other cohorts. Likewise, proportions of TFH 
expressing high levels of ICOS were also significantly elevated 
relative to mock-infected controls, which was also the case for 
VSV-infected mice albeit to a lesser extent. Surprisingly, while 
proportions of B cells expressing PD-L1 similarly increased 
(Figure  3D), those expressing ICOSL were reduced whereas 
the ligand pair CD40:CD40L remained unchanged across the 
three infection groups (Figures  3C,D). Serum levels of BAFF 
were also elevated in LCMV Cl13-infected mice along with 
BAFF, IL-21, and IL-4 mRNA and protein expression in CD4 
T cells (Figures  3E,F). As previously mentioned, predilection 
toward TFH differentiation in the context of persistent infection 
can occur as a result of prolonged expression of IFN-I. However, 
whether the effects on the humoral response are solely due to 
a modulated TFH response shaping the B cell response or more 
direct impact of IFN-I on the B cells is unknown. To determine 
the potential role of TFH immunomodulation on perturbation 
of the humoral response, we administered blocking Abs against 
PD-1, which comprises a key molecular interaction between GC 
B cells and TFH (42). The LCMV WE strain was used here given 
that interfering with the PD-1 pathway during the early phase of 
systemic LCMV Cl13 infection has been shown to induce lethal 
CD8 T cell-mediated immunopathology (18, 43). As illustrated 
in Figure 3G, blockade of PD-1 prior to infection and immu-
nization with NP did not alter the NP-specific and total IgG 
titers relative to the untreated control group. Similar results were 
obtained following PD-L1 blockade (data not shown). Therefore, 
in our model, humoral disruption was immutable to blockade 
of the PD-1 pathway suggesting a more direct role of IFN-I on 
B cell function.
FigUre 3 | lcMV infection triggers the expansion of TFh cells and induces their expression of B cell-activating cytokines. B6 mice (four per group) 
were infected with LCMV Cl13 (black bars or lines), LCMV WE (hatched), VSV (gray bars or dotted lines), or mock infected (white bars or shaded area). Mice 
were immunized the same day with an i.p. injection of NP53-CGG in alum and CD4+ T cells were analyzed on d8 after infection. (a) Total CD4+ T cell numbers 
(top panel) and proportions (bottom panel) determined by flow cytometry. (B) TFH cell numbers and proportions determined by flow cytometry. (c) Proportion of 
TFH cells expressing PD-1, ICOS, and CD40L and (D) B cells expressing PD-L1, ICOSL, and CD40 determined by flow cytometry. (e) Serum BAFF concentration 
(left panel) and BAFF mRNA expression in total splenic CD4 T cells (right panel) measured using ELISA and qRT-PCR, respectively. (F) Intracellular cytokine 
levels (left panel) and mRNA expression (right panel) of IL-4 and IL-21 in CD4 T cells measured using flow cytometry and qRT-PCR, respectively. (g) NP-specific 
IgG1 response (left panel) and total IgG response (right panel) monitored upon infection with LCMV WE (hatched bars), VSV (gray), or mock-infected (white) 
infection along with injection of PD1-blocking Ab (red hatched or checkered bars). Statistical analysis was performed by individual T-tests between experimental 
groups and the mock-infected group and between non-treated and anti-PD1 Ab-treated LCMV-infected groups when indicated with brackets. *p < 0.05, 
**p < 0.01, and ***p < 0.001. (a,B) Representative of four independent experiments. (c–e,g) Representative of two independent experiments. 
(F) Representative of three independent experiments.
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FigUre 4 | iFn-i acts in competition with Bcr signaling to induce B cell survival and proliferation. (a) Serum level of IFN-I in B6 mice (n = 4) infected with 
LCMV Cl13 (black), LCMV WE (hatched), or VSV (gray) measured using ELISA. Statistical analysis was performed by T-test between LCMV and VSV-infected 
groups. ***p < 0.001. (B–D) 2 × 106 B cells from WT B6 (white bars) or IFNAR −/− (black bars) mice were cultured for 7.5 h (for proliferation and CD69 expression) or 
4 days (for survival) without in vitro stimulation (solid dark gray), or with α-IgM (light gray line), IFN-β (black dotted line), or both (black line). (B) 7-AAD exclusion, (c) 
CFSE dilution, and (D) CD69 expression were measured by flow cytometry. Representative of two independent experiments.
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iFnar signaling is essential for  
lcMV-Mediated humoral immune 
response Disruption
Previous studies have demonstrated a rapid and robust increase 
in LCMV-induced IFN-I levels in the serum (16, 17), which, as 
illustrated in Figure 4A, was also observed in our LCMV cohorts 
as well as in VSV-infected mice albeit to a much lesser extent and 
for a shorter duration. Next, we performed in vitro stimulation 
of B cells with IFN-β in the presence or absence of BCR signal-
ing to evaluate any modifications in survival and proliferation. 
Here, B cell samples were harvested from both wild-type B6 and 
IFNAR−/− mice to determine specific action by IFN-I. As shown 
in Figure 4B and consistent with a previous study (24), addition 
of IFN-β in the WT B cell culture sustained B cell survival by 
fivefold after 4  days, whereas B cells from IFNAR−/− mice did 
not respond to IFN-β, as expected. Of note, IFN-I stimulation 
in this setting is likely equivalent to acute infection and our 
results are in agreement with the impact of IFN-I on B cells as 
shown in previous reports (23, 25, 27–29). Interestingly, upon 
stimulation through the BCR, survival of cultured B cells was 
diminished regardless of addition of IFN-β. Furthermore, while 
BCR stimulation increased B cell proliferation, the addition of 
IFN-β completely abrogated the BCR-dependent increase in 
proliferation (Figure 4C). We also measured B cell activation by 
evaluating expression of the activation marker CD69 upon which 
we found that IFN-β increases B cell activation independently 
of BCR stimulation (Figure  4D). Given the enhancement of 
survival independent and antagonistically to BCR signaling, 
these results suggest that IFN-I signaling could potentiate the 
increase of non-specific B cells while impairing the development 
of antigen-specific B cell responses.
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To directly evaluate the effect of IFN-I signaling on the 
humoral response in our in  vivo model, we performed LCMV 
Cl13 infection and co-immunization with NP in mice that were 
treated with either IFNAR blocking or isotype control Abs. 
Although IFNAR blockade prior to LCMV Cl13 infection has 
been shown to enhance viral clearance in a CD4 T cell-dependent 
manner (16, 17), its impact on the Ab response during the pro-
gression of a chronic infection has not been thoroughly assessed. 
As depicted in Figure 5A, LCMV-specific-binding Ab responses 
were not significantly affected by IFNAR blockade as observed 
in previous reports (16, 17). Remarkably, however, NP-specific 
serum IgG1 titers were restored to levels present in VSV- or 
mock-infected animals upon IFNAR blockade (Figure  5B). In 
addition, restoration of the anti-NP IgG1 response was observed 
following either: a single anti-IFNAR administration conducted 
on d-1 prior to the infection/immunization (Figure  5C) or a 
series of 11 anti-IFNAR treatments conducted every third day 
until d30 postinfection/immunization (Figure 5D). Despite this 
result, it is important to note that the effect of the short-term Ab 
treatment regimens seemingly waned over time (Figures 5B,C). 
IFN-I has been shown to induce CSR primarily toward an 
IgG2a/c subtype (27). To ascertain that the LCMV-associated 
depletion of NP-IgG1 responses was not solely due to the skew 
toward NP-specific IgG2c responses, we assessed whether the 
recovery of NP-specific IgG1, upon IFNAR blockade, was 
inversely related to IgG2c titers in our experimental cohorts. 
As shown in Figure  5E, although low-level NP-specific IgG2c 
titers were detected starting on d12 following immunization 
in LCMV-infected mice compared to the mock-infected group, 
similar levels were also observed in the VSV-infected group 
indicating a general effect driven by viral infection. Expectedly, 
IFNAR blockade reduced NP-specific IgG2c titers in LCMV-
infected mice denoting a role for IFN-I in the observed CSR to 
IgG2c. These results indicate that, the IFN-I response generally 
elicited during all viral infection induces CSR to IgG2c of some 
antigen-specific B cells, and this effect is unlikely limited to 
LCMV infection or more broadly, persistent infections; thus, 
neither the diminished NP-specific IgG1 Ab response observed 
during LCMV infection nor its recovery upon IFNAR blockade 
is accounted for by a skewing toward or away from IgG2c 
responses. Altogether, these results affirm that the suppressive 
effect observed on the NP-specific IgG1 response during LCMV 
infection is dependent on IFN-I signaling and independent of 
CSR to IgG2c. Finally, consistent with a previous report that 
showed the induction of HGG in IFNAR−/− mice following 
LCMV infection (38), HGG was unchanged by any of the IFNAR 
blockade regimen (Figures 5F–H).
We next evaluated the impact of IFNAR blockade on the TD 
B cell response during LCMV infection. Consistent with the 
normalized IgG1 response against NP, the number of NP-specific 
IgG-secreting cells returned to that found in VSV- or mock-
infected animals (Figure 6A, right panel) upon IFNAR blockade 
while total IgG-secreting cells remained elevated (Figure  6A, 
left panel), in agreement with sustained HGG. Surprisingly, 
although IFNAR blockade led to the restoration of total 
splenic CD4+  T cell proportions (Figure  6B), the increase in 
TFH observed following LCMV infection remained unchanged 
(Figure  6C). Moreover, the treatment bore limited impact on 
IL-4 and IL-21 expression in CD4 T cells (Figure  6D), GC 
B cell proportions (Figure  6E), and relative Ab secretion by 
ASCs (Figure  6F). However, relative to the isotype control, 
anti-IFNAR treatment resulted in moderate modulation in the 
expression levels of PD-L1, ICOSL, and ICOS (Figures 6G,H). 
As observed, TFH and GC B cell populations remained elevated 
upon IFNAR blockade despite the recovery of NP-specific Abs. 
Next, we sought to determine whether the structure of B cell 
follicles was restored upon IFNAR blockade similar to the rescue 
of lymphoid architecture as described in previous reports (16, 
17, 20). Here, we observed that only incomplete recovery of 
the B cell follicle structure occurred suggesting that LCMV 
infection induces disruption of B cell localization in a partially 
IFNAR-independent manner (Figure 6I). Based on the role of 
CXCR4 in the trafficking of B cells in lymphoid follicles and 
resultantly their structure (44), we examined its expression level 
upon IFNAR blockade. As shown in Figure  6J, left panel, we 
observed a remarkable elevation in CXCR4 expression in total B 
cells, which was restored to base levels upon IFNAR blockade. 
Surprisingly however, this increase in CXCR4 expression levels 
was not observed in the GC compartment in the LCMV-infected 
group compared to VSV- or mock-infected animals (Figure 6J, 
right panel). Nonetheless, IFNAR blockade also significantly 
reduced CXCR4 expression in GC B cells. These results illustrate 
a significant role played by IFN-I produced during LCMV 
infection in altering CXCR4 expression and consequently the 
trafficking and localization of B cells outside of follicular struc-
tures. This interplay suggests a mechanistic outline by which 
IFN-I modulates the humoral immune response.
B cell-intrinsic iFn-i signaling Directly 
Disrupts the antigen-specific humoral 
response
Our data so far have suggested an effect of IFN-I on B cells. 
Therefore, to determine the role of B cell-intrinsic IFN-I 
signaling on the impaired humoral response observed during 
LCMV infection, we developed a chimeric model by recon-
stituting irradiated B6 mice with a mix of bone marrow cells 
from B cell-deficient (JHT) mice (45) and IFNAR−/− mice. As 
a result, we obtained chimeras in which only the B cells are 
deficient in IFN-I signaling. Upon LCMV Cl13 infection and 
NP-CGG immunization of JHT/IFNAR−/− chimeras, we observed 
restoration of the NP-specific response to levels observed in 
the VSV- or mock-infected B6 mice (Figure  7A), which was 
consistent with the IFNAR blockade experiment. Interestingly, 
whereas IFNAR blockade did not ameliorate HGG, the levels 
of total serum IgG in LCMV Cl13-infected JHT/IFNAR−/− chi-
meras were significantly lower than those in WT animals and 
normal relative to VSV and mock-infected mice (Figure  7B). 
Yet, despite the normalization of humoral immune responses, 
JHT/IFNAR−/− mice still exhibited only partial rescue of the 
splenic marginal-zone and B cell follicle structures (Figure 7C). 
Perhaps the most significant impact observed by the absence of 
B cell-specific IFNAR signaling was the accelerated emergence 
of nAbs in the chimeras compared to both JHT/B6 chimeras, 
FigUre 5 | iFnar blockade restores nP-specific igg1 responses during lcMV infection. B6 mice (four per group) were treated with α-IFNAR Ab (red), 
isotype control Ab (hatched), or left untreated (black) and were infected the next day with LCMV Cl13, VSV (gray), or mock infected (white). Mice were immunized 
the same day with an i.p. injection of NP53-CGG in alum. (a,B,e,F) IFNAR blockade was conducted every second day until d8. In another series of experiments, 
anti-IFNAR treatment was stopped after either one injection (d-1) (c,g) or 11 injections every third day (d30) (D,h). (a) LCMV nucleoprotein-specific IgG titers, 
(B–D) NP-specific IgG1, (e) NP-specific IgG2c, (F–h) total IgG titers monitored by ELISA. Statistical analysis was performed by individual T-tests between 
experimental groups and the mock-infected group. *p < 0.05, **p < 0.01, and ***p < 0.001. The dotted line represents detection threshold. Representative of two 
independent experiments.
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FigUre 6 | iFnar blockade partially restores TD B cell responses and splenic follicular structures. B6 mice (four per group) were treated with α-IFNAR 
Ab (checkered) or isotype control Ab (black) and were infected the next day with LCMV Cl13, VSV (gray), or mock infected (white). Mice were immunized the day of 
the infection with an i.p. injection of NP53-CGG in alum. IFNAR blockade was conducted every second day until analysis on d8. (a) Number of total (left panel) and 
NP-specific IgG-secreting (right panel) cells detected by ELISPOT. (B) Proportion of CD4 T cells among total lymphocytes and (c) total numbers (left panel) and 
proportions (right panel) of TFH cells among total CD4 T cells as determined by flow cytometry. (D) Intracellular IL-4 and IL-21 levels in TFH cells and (e) proportion of 
splenic GC B cells determined by flow cytometry. (F) Secretory capacity of ASCs as determined by measuring the quantity of secreted Abs produced by 105 
splenocytes. (g) Proportion of B cells expressing PD-L1, ICOSL, and CD40. (h) Proportion of TFH cells expressing PD-1, ICOS, and CD40L. (i) Splenic follicular 
structures visualized using immunofluorescent staining of CD19 (red), MOMA-1 (green), and DAPI (blue) in tissue sections. (J) Proportion of CXCR4+ B cells among 
total (left panel) and GC B cells (right panel) determined by flow cytometry. Statistical analysis was performed by individual T-tests between experimental groups and 
the mock-infected group and between isotype and IFNAR blocking Ab-treated groups when indicated with brackets. *p < 0.05, **p < 0.01, and ***p < 0.001. 
(a,J) Representative of three independent experiments. (B–i) Representative of two independent experiments.
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FigUre 7 | B cell-specific disruption of iFnar restores nP-specific ab responses and accelerates the development of lcMV nabs. (a–c) B6, JHT/
IFNAR−/−, or JHT/B6 mice (four per group) were infected with LCMV Cl13 (black for B6; red for JHT/IFNAR−/−), VSV (gray), or were mock infected (white). Plain bars 
represent B6 mice and checkered bars JHT/IFNAR−/− B cell bone marrow chimeric mice. (a) NP-specific IgG1 and (B) total IgG responses monitored using ELISA on 
d8 following infection/NP53-CGG immunization. (c) Splenic follicular structures visualized using immunofluorescent staining of CD19 (red), MOMA-1 (green), and 
DAPI (blue) on spleen sections obtained on d8 postinfection. (D) Neutralization assay showing accelerated nAb responses in JHT/IFNAR−/− chimeric mice upon 
infection with LCMV Cl13. (a–c) Representative of two independent experiments. (D) Compilation of three independent experiments (B6 mice, n = 21; JHT/
IFNAR−/− mice, n = 25; JHT/B6 mice, n = 8). Statistical analysis was performed by individual T-tests between experimental groups and the mock-infected group for 
(a–c) and one-way ANOVA for (D). *p < 0.05, **p < 0.01, and ***p < 0.001. The dotted line represents detection threshold.
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used as controls to account for any changes driven by irradia-
tion and reconstitution and more importantly, WT B6 mice 
(Figure 7D). The fact that JHT/B6 chimeras did not produce any 
detectable LCMV nAbs suggests that only partial reconstitution 
of the humoral response was achieved in the chimeric system. 
This result further underscores the significance of the acceler-
ated nAb response observed in the JHT/IFNAR−/− chimeras. 
Collectively, these data illustrate a potent effect borne by IFN-I 
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signaling on B cells, which upon negation results in a normal 
NP-specific humoral response as well as enhanced induction 
of LCMV nAbs.
DiscUssiOn
The immune response in the LCMV infection model has been 
classically defined as cell mediated (46) whereas the role of the 
humoral immune response has only been considered relevant in 
the context of reinfection (47). Although the absence of an initial 
robust nAb response has been primarily attributed to antiviral 
escape mechanisms (32, 48), the immunological processes that 
drive the disruption of humoral immunity during persistent 
infection are yet to be elucidated.
In this report, we reveal that emergence of humoral dysfunc-
tion during LCMV infection occurs in an IFN-I-dependent 
manner in which antigen specificity in the TD immune response 
was impaired; this effect was notably more evident in LCMV 
Cl13- relative to WE-infected animals. To gain deeper insight 
into the nature of immunological impairment, we tracked the 
immune response against NP rather than the actual viral antigens 
in different experiments to distinguish viral specific effects from 
global immune responses. Collectively, the presence of humoral 
disruption observed with both LCMV strains illustrates that 
pathogenic mechanisms present in the acute phase of infection as 
well as sustenance of viral burden in the face of prolonged LCMV 
Cl13 infection both play a role in the observed perturbations. 
However, this impairment is not a universal consequence of 
any viral infection or of IFN-I production per  se as infection 
with VSV, which also promotes IFN-I production, albeit to a 
lesser extent than LCMV, does not lead to a disrupted humoral 
response; as such, LCMV-specific factors also likely play a role 
in the muted Ab response. Whereas blockade of IFN-I signaling 
using anti-IFNAR Abs reestablished the anti-NP response, HGG 
remained present consistent with a previous report in IFNAR−/− 
(38) and the expansion of the TFH and total IgG-secreting cell 
populations was still observed. Furthermore, the expression of 
costimulatory molecules between B and T cells was partially 
restored to levels intermediate between isotype treated and VSV-
infected controls. In addition, treatment with anti-PD-1/PD-L1, 
which was conducted prior to infection and co-immunization, 
bore no impact on LCMV-mediated dysregulation. These find-
ings along with the observed effect of IFN-I on B cell survival 
and proliferation in  vitro suggested that LCMV-induced IFN-I 
acted directly on B cells. The significance of this interaction 
was demonstrated using JHT/IFNAR−/− chimeric mice in which 
only B cells carried the receptor knockout. Remarkably, the 
absence of IFN signaling on B cells restored normal humoral 
function with NP-specific Ab titers similar to those observed in 
VSV- or mock-infected mice. Moreover, B cell-specific IFNAR 
ablation normalized HGG consistent with a recent report in the 
Leishmania infection model (49). In light of the incapacity of 
IFNAR blockade to limit HGG, this suggests that IFN-I signaling 
on cells other than B cells also contributes to regulating HGG 
development although the exact nature of this contribution 
remains to be defined. Altogether, these results revealed the role 
of IFN-I signaling on B cells in impairing Ag-specific responses 
albeit possibly indirectly through the abnormal expansion of 
non-specific B cells.
Along with the recovery of the antigen-specific humoral 
response, we observed a reduction in the extent of destruction 
to splenic follicular architecture upon both the blockade and 
B cell-specific knockout of IFNAR. Similar to the recovery of the 
general splenic tissue organization observed in previous studies 
(16, 17), we surmise that this occurs in part due to preservation 
of cellular trafficking and localization in the splenic microstruc-
ture. Shuttling back and forth between the light zone (LZ) and 
dark zone (DZ) of the GC is actuated by differential expression 
of chemokine receptors such as CXCR4 and CXCR5 (50, 51). 
Upon analysis of CXCR4 expression on B cells, we observed that 
the LCMV-associated increase in total B cells was completely 
reversed by anti-IFNAR Ab administration. However, since 
CXCR4 expression on GC B cells was unchanged upon LCMV 
infection, we surmise that the overall increased expression of 
the chemokine receptor upon infection most likely occurred in 
extrafollicular B cells. It is important to note that this change to 
cellular trafficking and localization likely represents only a frac-
tion of similar such changes that alter splenic structure during 
LCMV infection.
In addition, these changes to B cell trafficking also suggest 
altered positive selection thresholds of effector cells. This pos-
sibility is further advanced by the increase in GC B cell numbers 
as well as the expansion of the non-specific ASC population. 
Along with the observation of TFH increase in LCMV-infected 
animals, we deduce that the positive selection process in which 
antigen-specific B cell clones compete for survival signals from 
TFH is dysregulated. In this setting, the threshold for positive 
selection is lowered based on the aberrant expansion of TFH cells. 
As a result, B cells exhibiting lower antigen specificity or non-
specificity, which in the normal functional setting would not be 
selected, receive survival signals. Consequently, this expansion of 
non-specific B cells diminishes the likelihood of cognate TFH–B 
cell interactions taking place in a productive manner, which 
leads to an impairment of specific Ab responses (see Figure  8 
for proposed model). However, the affinity maturation process 
is still intact despite this disruption based on the stability of the 
high affinity NP4-BSA Ab titers in all the infection groups. Thus, 
the positive selection mechanism is functional yet stunned by 
the influx of non-specific B cell clones. Most significantly, the 
accelerated LCMV nAb response observed in the JHT/IFNAR−/− 
chimeras relative to WT B6 and JHT/B6 can also be accounted for 
by such a mechanism. In this setting, the WT response features 
increased activation of non-specific B cell clones. Consequently, 
the response to neutralizing epitopes, which are immunoreces-
sive, is further diminished by the effects of IFN-I signaling. This 
is a significant characterization given that the elicitation of nAbs 
and moreover, broadly nAbs, is also delayed in chronic infection 
settings such as HIV and HCV whose immunological profiles 
closely mirror those observed in LCMV.
Another important aspect of human persistent virus infection 
is poor vaccination responses in infected patients. Using NP co-
immunization, our model recapitulates the diminished response 
against a secondary antigen and elucidates the role played by 
IFN-I-mediated signaling in the chronic infection setting. Other 
FigUre 8 | Proposed schematic of B cell selection during a normal versus impaired humoral immune response during lcMV infection. In (a), antigen 
specificity of the resultant Ab response is facilitated by effective selection of B lymphocytes in the LZ of the GC response. Some of these cells migrate to the 
periphery as effector cells while others cycle back into the DZ for proliferation in an iterative process. During LCMV and more generally, other chronic infections 
(B), the high concentration of IFN-I along with sustained elicitation and TFH expansion triggers selection of non-specific B cells in the context of a disrupted follicular 
architecture; as such, antigen-specific effector cells and consequently, Ab responses, are “drowned” out by the influx of non-specific cells. This figure only 
represents a snapshot of the process in which the immune response is further honed in (a), whereas the dilution and loss of specificity in (B) is exacerbated in 
subsequent rounds.
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studies have also shown that poor responses against vaccines are 
correlated with an increased PD-1:PD-L1 profile in HIV and 
HCV infected patients (10, 52).
In conclusion, the lack of an effective humoral immune 
response during LCMV infection is driven by general modula-
tion to the humoral immune microenvironment by IFN-I. This 
modulation is limited to the TD response and is established early 
following infection; as well, blockade of IFN-I-mediated effects 
allows the immune response to proceed normally. Altogether, 
there are many aspects of the immune response to consider 
in their entirety, but the significance of IFN-I signaling offers 
an ideal anchor for future analysis and provides a therapeutic 
target against persistent viral infections to potentially boost Ab 
responses as well as limit immunopathogenesis.
MaTerials anD MeThODs
ethics statement
All animal experiments were reviewed and approved by the 
Institut national de la recherche scientifique (INRS) animal 
care committee under protocol 1302-05 and in accordance with 
AAALAC and Canadian Council on Animal Care (CCAC) 
guidelines.
Mice, infections, and immunizations
Six- to eight-week-old B6 female mice were purchased from 
Charles River Laboratories (St-Constant, QC, Canada). JHT mice 
were obtained from Rolf M. Zinkernagel, Zurich, Switzerland. 
IFNAR−/− mice on a B6 background were obtained from Ulrich 
Kalinke, Hannover, Germany. All mice were maintained at the 
INRS animal facility until use.
To generate mixed bone marrow chimeric mice, bone marrow 
cells from 8- to 12-week-old B6, JHT, and IFNAR−/− mice were 
mixed at a ratio of 4:1 (JHT/IFNAR−/− or JHT/B6) and injected 
intravenously (i.v.) into lethally irradiated (2 × 600 rads) B6 mice. 
Mice were left untouched for ≥5  weeks to allow for immune 
reconstitution as determined by flow cytometry.
All viral strains used in this paper were obtained from Rolf M. 
Zinkernagel, Zurich, Switzerland. Infections with LCMV Cl13, 
LCMV WE, or VSV Indiana were carried out by i.v. injection with 
2 × 106 pfu of virus or with culture media alone (mock).
For T cell-dependent Ab response characterization, mice were 
immunized intraperitoneally (i.p.) with 50 μg alum-precipitated 
4-Hydroxy-3-nitrophenylacetic hapten conjugated to CGG 
(NP-CGG; Biosearch Technologies, Petaluma, CA, USA), at a ratio 
of 53:1, or with precipitated alum alone as a control. For T cell-
independent Ab response characterization, mice were immunized 
i.p. with 5 μg 4-hydroxy-3-nitrophenylacetic hapten conjugated 
to AminoEthylCarboxyMethyl-FICOLL (NP-FICOLL; Biosearch 
Technologies, Petaluma, CA, USA) in PBS, at a ratio of 40:1, or 
with PBS alone as a control. All mice were maintained under 
specific pathogen-free conditions and immunizations or adoptive 
transfers were carried out at 6–10 weeks of age.
Blocking Abs were used to block PD-1 and IFNAR signaling. 
For PD-1 blockade, 250  μg of blocking Ab or isotype control 
(BioXcell, West Lebanon, NH, USA) were injected i.p. every 
3 days starting 1 day before infection and continuing throughout 
the whole experiment. For IFNAR blockade, 500 μg of blocking 
Ab or isotype control (Leinco Technologies) were injected i.v. 
every 2–3  days starting 1  day before infection and stopping at 
various time points as indicated.
B cell In Vitro stimulation and cFse 
staining
Splenic B cells were isolated using the EasySepTM Mouse B Cell 
Enrichment Kit (Stemcell Technologies, Vancouver, BC, Canada) 
according to the manufacturer’s instructions. B cells were resus-
pended to 2 × 107 cells/mL in PBS containing 2% FBS and CFSE 
(Fisher, Waltham, MA, USA) was added to a final concentration 
of 1 μM. Samples were incubated for 5 min at room temperature 
and staining was quenched by addition of an equal amount of 
FBS. Cells were washed with PBS/2% FBS and resuspended 
in RPMI-1640 medium supplemented with 10% FBS, 2  mM 
glutamine, 100  U/mL penicillin, 100 μg/mL streptomycin, and 
55 μM 2-mercaptoethanol. The 3 ×  106  cells/well were seeded 
in 24-well plates and stimulated with either 10 μg/mL goat anti-
mouse IgM (Jackson Immunoresearch, West Grove, PA, USA) 
and 500 U/mL mouse IFN-β (Quansys Biosciences, Logan, UT, 
USA) or respective combinations and cultured (37°C, 5% CO2) 
for either 7.5 h or 4 days.
antibodies and Detection reagents
The following staining reagents were used: anti-CD3 (145-2C11), 
anti-CD4 (H129.19), anti-CD62L (MEL-14), anti-CD44 (IM7), 
anti-CD45R (RA3-6B2), anti-PD-1 (29F.1A12), anti-PD-L1 
(10F.9G2), anti-ICOSL (HK5.3), anti-CD40 (HM40-3), anti-
CD40L (MR1), anti-CXCR4 (L276F12), and anti-IL-4 (11b11) 
were from Biolegend (San Diego, CA, USA); anti-CD19 (eBio1D3), 
anti-ICOS (7E.17G9), anti-IL-21 (mhalx21), anti-CD69 (H1.2F3), 
and anti-GL7 (GL-7) were from eBiosciences (San Diego, CA, 
USA); anti-Bcl-6 (K112-91), anti-CXCR5 (2G8), and anti-Fas 
(Jo2) were from BD Biosciences (Franklin Lakes, NJ, USA). PNA 
(B-1075; Vector Laboratories, Burlington, ON, Canada) was 
used for staining germinal center B cells and MOMA-1 (Abcam, 
Cambridge, UK) for staining MZ macrophages.
Flow cytometry
Single-cell suspensions of splenocytes were stained on ice with 
the appropriate Abs in PBS containing 1% (v/v) bovine serum 
albumin (BSA, Fisher, Waltham, MA, USA) and 0.1% (w/v) 
sodium azide (GE Healthcare, Mississauga, ON, Canada). Non-
specific staining was blocked by 2.4G2 Ab against CD16/32 
[Biolegend; prepared as previously described (53)]. Samples 
were fixed with 1% (v/v) paraformaldehyde and analyzed on a 
BD LSR II Fortessa (BD Bioscience). For intracellular cytokine 
staining, splenocytes were stimulated ex vivo for 5 h with phor-
bol 12-myristate 13-acetate (PMA, Sigma-Aldrich, Saint-Louis, 
MI, USA) (100  ng/mL), ionomycin (Sigma-Aldrich) (1  μM), 
and Brefeldin A (Sigma-Aldrich) (10  μg/mL). Samples were 
fixed and permeabilized prior to incubation with Ab in permea-
bilization buffer (eBiosciences). Dead cells were excluded based 
on positive staining with 7-Amino-Actinomycin D (7-AAD) 
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(BD Pharmingen), and doublets gated out using FSA-A/SSC-A. 
Data were analyzed with FlowJo software (TreeStar, Ashland, 
OR, USA).
Quantitative rT-Pcr
CD4+ T cells were magnetically selected using the EasySep 
system (StemCell, Vancouver, BC, Canada), frozen, and con-
served at −80°C. Total RNA was isolated using the RNeasy Mini 
kit (Qiagen, Hilden, Germany) and quantified by Nanodrop 
ND-1000 (Fisher, Waltham, MA, USA). cDNA was synthesized 
from total RNA using the Superscript III First-Strand Synthesis 
SuperMix (Applied Biosystems) and frozen at −80°C until use. 
Gene expression was determined by quantitative PCR using 
TaqMan Gene expression System (Life Technologies, Burlington, 
ON, Canada) on a Rotor-gene 6000 system (Corbett, Concorde, 
NSW, Australia). Standard commercial TaqMan probes were 
used for IL-4, IL-21 and BAFF (Life Technologies). Samples 
were normalized to GAPDH and represented as fold change over 
mock-infected mice using the ΔΔCT method (54).
elisa and elisPOT assay
For NP-specific serum Ig detection, 96-well plates (Mabtech, 
Cincinnati, OH, USA) were coated overnight at 4°C with 
0.1 μg of NP-BSA conjugated at a ratio of NP to BSA ranging 
from 4:1 to 26:1. For total serum IgG detection, microtiter 
plates were coated overnight at 4°C with unlabeled anti-IgG 
(Jackson ImmunoResearch, West Grove, PA, USA) at 2  μg/
mL. Non-specific binding was blocked with 10% (v/v) fetal 
bovine serum and 0.2% (v/v) Tween 20 in PBS. Horseradish 
peroxidase (HRP)-conjugated secondary Abs: anti-IgM, anti-
IgG1, anti-IgG2c, anti-IgG3, and anti-IgG (total IgG) (Jackson 
ImmunoResearch, West Grove, PA, USA) were detected with 
0.04% (w/v) o-phenylenediamine and 0.8% H2O2 (v/v) in citrate 
buffer. Serum BAFF detection was done by coating 96-well plates 
overnight at 4°C with 2  μg of anti-BAFF Ab (R&D Systems, 
Minneapolis, MN, USA) in carbonate buffer. Non-specific bind-
ing was blocked with 1% (v/v) BSA in PBS. HRP-conjugated 
anti-BAFF secondary Ab (R&D Systems) was detected with 
0.04% (w/v) o-phenylenediamine and 0.8% H2O2 (v/v) in citrate 
buffer. Serum IFN-α and -β detection was done using Verikine 
kits (PBL Assay Science, Piscataway Township, NJ, USA) in con-
ditions recommended by the company. LCMV nucleoprotein-
specific IgG serum Abs were determined by ELISA using plates 
coated with purified recombinant LCMV nucleoprotein-GST as 
previously described (55).
For ASC determination by ELISPOT, a mouse IgG ELISPOTPlus 
kit (Mabtech, Nacka Strand, Sweden) was used. Briefly, 96-well 
nitrocellulose plates (Millipore, Etobicoke, ON, Canada) were 
coated overnight at 4°C with anti-IgG antibody. Non-specific 
binding was blocked with 5% (v/v) FBS in PBS. Cell suspensions 
obtained from spleens were added to wells (104 cells for detection 
of IgG and 105 for NP) in duplicate and incubated overnight at 
37°C in a 5% CO2 atmosphere. B cell spots were developed by 
sequential washes with PBS, addition of biotinylated anti-IgG 
or NP-BSA-Biotin, washes with PBS, addition of streptavidin-
alkaline phosphatase, washes with PBS and addition of 5-Bromo-
4-chloro-3-indolyl phosphate substrate for 15  min. Spots were 
counted using an AID Elispot Reader (Autoimmun Diagnostika 
GmbH, Strasberg, Germany).
immunochemistry
Freshly harvested spleens were flash frozen in OCT (Electron 
Microsopy Sciences, Hartfield, PA, USA) in liquid nitrogen, 
stored at −80°C and processed for sets of 10-μm section sizes with 
a cryostat (Microm HM 525; GMI, Ramsey, MN, USA). Tissue 
sections were fixed on slides in 75% acetone and 25% ethanol 
(v/v) for 5 min and incubated with primary reagent in PBS for 
1 h at room temperature. The following primary reagents were 
used: anti-mouse CD19-PE (RA3-6B2, eBiosciences, 1:10000) 
and anti-mouse MOMA-1-FITC (Abcam, Toronto, ON, Canada, 
1:200). Tissue sections were then washed in PBS and incubated 
with a secondary Alexa 488 anti-FITC (Life Technologies) to 
amplify FITC signal or strep-A488 if needed. Tissue sections were 
then mounted with Prolong (Life Technologies), dried overnight, 
and observed using a LSM780 confocal microscope (Carl Zeiss, 
Oberkochen, Germany).
ab secretion Quantification
Freshly prepared splenocyte suspensions were plated in triplicates 
in 96-well flat bottom plates at 105 cells per well in culture medium 
containing DMEM, 10% FBS, 1% streptavidin/penicillin, 1% 
l-glutamine, 1% sodium pyruvate, and β-mercaptoethanol. Cells 
were incubated for 48 h at 37°C and culture media was harvested 
to quantify Ab by ELISA. This quantitation was compared to 
the numeration of ASCs obtained using ELISPOT to define an 
individual secretion per ASC cell.
lcMV nab Quantification
Lymphocytic choriomeningitis virus nAbs were quantified as 
described previously (56). In brief, serial 2-fold dilutions of 
10-fold prediluted sera were incubated with LCMV for 90 min 
at 37°C in 96-well plates. MC57G mouse fibroblasts were added 
and incubated for 1 h to allow cells to settle and be infected by 
non-neutralized virus; cells were then overlaid with 1% methyl-
cellulose in MEM. After 48  h, cell monolayers were fixed with 
4% formalin and infectious foci were detected by intracellular 
LCMV staining of infected cells with rat anti-LCMV mAb VL-4.
statistical analysis
Data were analyzed using Prism 6 (GraphPad Software, Inc.). 
Statistical significance was assessed as indicated using unpaired 
two-sided T-test, or a one-way ANOVA with Tukey’s multiple 
comparisons test. p Value <0.05 was considered significant. 
*p < 0.05, **p < 0.01, and ***p < 0.001. Data are represented as 
means ± SD.
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with an i.p. injection of NP53-CGG in alum following a varying immunization 
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timed experiment monitored by ELISA. (B) ELISA plates were coated with 
NP4-BSA or NP26-BSA and high affinity Ab responses were measured as a ratio 
of Abs binding to NP4-BSA versus the total anti-NP IgG1 response binding to 
NP26-BSA in each differentially timed experiment. Statistical analysis was 
performed by individual T-tests between experimental groups and the 
mock-infected group. *p < 0.05, **p < 0.01, and ***p < 0.001.
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